Global Opioids Market Analysis 2026

According to Cognitive Market Research, the Global Opioids Market Size was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

•     The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
•     The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
•     The hospital pharmacies had a market share of about XX% in 2023.
•     The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
•     The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
•     The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
•     North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Introduction of Opioids Market

Opioids are medicines that are used for the treatment of persistent and severe pain, such as chronic backaches and headaches as well as for managing pain after surgery. It is a class of drugs that act on the nervous system to relieve pain. They are derived from opium or synthetic versions that mimic the effects of natural opium compounds. Many patients rely on prescribed opioids to help them manage their ailments while under the care of a doctor. When it comes to reducing moderate to severe pain, opioids are very effective. They reduce the experience of pain by attaching to opioid receptors in the brain, spinal cord, and other areas of the body. When someone is in excruciating pain following surgery, an injury, or a medical condition like cancer, opioids can be a lifesaver. They can also be applied in palliative care to lessen suffering towards the end of life. The opioid market is witnessing growth owing to the increasing prevalence of orthopedic diseases and chronic pain, rising focus on the abuse-deterrent formulation (ADF), rising palliative care facilities, and inclination towards extended-release formulations from the immediate release of opioids. The increase in ailments including cancer, lung infections, HIV, and an expansion in surgical procedures has fueled the growth of the opioid industry. The increasing approval and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth. For instance, in August 2020, the Food and Drug Administration in the U.S. approved Olinvyk (oliceridine), an injection developed by Trevena, Inc., for treating adults with acute pain. Olinvyk is an opioid agonist administrated intravenously to patients and costs around USD 194 for a supply of 10 mL.
(Source-https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings)